1397371-89-9

Upstream product

• 1338072-53-9 4-chloro-7-[3,5-O-(tetraisopropyldisiloxan-1,3-diyl)-β-D-arabinofuranosyl]-7H-pyrrolo[2,3-d]pyrimidine 
• 1397371-75-3 4-chloro-7-[2-O-acetyl-3,5-O-(tetraisopropyldisiloxane-1,3-diyl)-β-D-arabinofuranosyl]-7H-pyrrolo[2,3-d]pyrimidine 
• 1397371-80-0 4-chloro-7-[2-O-acetyl-β-D-arabinofuranosyl]-7H-pyrrolo[2,3-d]pyrimidine 
• 191543-71-2 methyl 3,5-di-O-benzyl-α-D-ribofuranoside 
• 817204-28-7 C₂₀H₂₂O₅ 
• 168608-39-7 (3S,4S,5R)-5-(((tert-butyldiphenylsilyl)oxy)methyl)tetrahydrofuran-2,3,4-triol 
• 532-20-7 D-arabinofuranose 

Downstream Products

• 1397372-04-1 4-phenyl-7-[2-deoxy-2-fluoro-β-D-ribofuranosyl]-7H-pyrrolo[2,3-d]pyrimidine 

Relevant academic research and scientific papers

NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO

This disclosure relates to nucleotide and nucleoside therapeutic compositions and uses related thereto. In certain embodiments, the disclosure relates to halogenated nucleosides optionally conjugated to a phosphorus oxide or pharmaceutically acceptable salts thereof. In certain embodiments, the disclosure relates to conjugate compounds or pharmaceutically acceptable salts thereof comprising an amino acid ester or a sphingolipid or derivative linked by a phosphorus oxide to a nucleotide or nucleoside. In certain embodiments, the disclosure contemplates pharmaceutical compositions comprising these compounds for uses in treating infectious diseases, viral infections, and cancer.

Synthesis of 2′-deoxy-2′-fluororibo- and 2′-deoxy- 2′,2′-difluororibonucleosides derived from 6-(het)aryl-7- deazapurines

A series of novel sugar-modified derivatives of cytostatic 6-hetaryl-7-deazapurine ribonucleosides (2′-deoxy-2′-fluororibo- and 2′-deoxy-2′,2-difluororibonucleosides) bearing an aryl or hetaryl group in position 6, was prepared and screened for biological activity. The fluororibo derivatives were prepared by aqueous palladium catalyzed cross-coupling reactions of the corresponding 6-chloro-7-deazapurine 2′-deoxy-2′-fluororibonucleoside 11 with (het)arylboronic acids. The key intermediate 11 was prepared by a six-step sequence from the corresponding arabinonucleoside by selective protection of 3′- and 5′-hydroxyls by acid-labile groups followed by stereoselective SN2 fluorination and deprotection. The difluororibo-series was prepared by non-stereoselective glycosidation of 6-chloro-7-deazapurine with benzoyl-protected 2-deoxy-2,2-difluoro-d-erythro-pentofuranosyl-1-mesylate followed by cross-couplings, separation of anomers and deprotection. The title nucleosides did not show considerable cytostatic or antiviral activity.